Dementia Alzheimer's type

20 trials 10 recruiting MedDRA PT
20 Registered trials
10 Recruiting
10 Unique sponsors
10 Unique IMPs
16 Commercial trials
Drug classes (ATC)
— ATC code not specified 18
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 10 substances
Phase III: 12 Phase II/III: 2 Phase II: 5 Phase I (Other): 1

Filter these 20 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 20 trials

Phase III

12 trials
  • Acadia Pharmaceuticals Inc. Commercial
    ACP-204 TARTRATE
    2023-507351-29-00 5 countries 2024 n=196
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE
    2024-516363-92-00 13 countries 2025 n=102
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2024-519994-20-00 11 countries n=193
    Pending
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2025-520612-34-00 5 countries 2025 n=92
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2025-520613-31-00 6 countries 2025 n=103
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2025-520746-30-00 8 countries 2025 n=225
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2025-520747-32-00 10 countries 2025 n=292
    Recruiting
  • Karuna Therapeutics Inc. Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE
    2023-504151-27-00 14 countries 2024 n=264
    Recruiting
  • Karuna Therapeutics Inc. Commercial
    IMP not specified
    2023-504416-16-00 4 countries 2024 n=186
    Ended
  • Otsuka Pharmaceutical Development & Commercialization Inc. Commercial
    QUINIDINE SULFATE, DEUDEXTROMETHORPHAN HYDROBROMIDE
    2023-504990-19-00 7 countries 2021 n=267
    Ended
  • Otsuka Pharmaceutical Development & Commercialization Inc. Commercial
    QUINIDINE SULFATE, DEUDEXTROMETHORPHAN HYDROBROMIDE
    2023-504991-31-00 8 countries 2021 n=248
    Ended
  • Suven Life Sciences Limited Commercial
    MASUPIRDINE
    2024-513835-25-00 2 countries 2022 n=157
    Recruiting

Phase II/III

2 trials
  • Institut National De La Sante Et De La Recherche Medicale Academic
    FLORTAUCIPIR (18F)
    2024-519995-20-00 1 country n=45
    Pending
  • Institut National De La Sante Et De La Recherche Medicale Academic
    IMP not specified
    2025-523264-21-00 1 country n=600
    Pending

Phase II

5 trials
  • Acadia Pharmaceuticals Inc. Commercial
    ACP-204 TARTRATE
    2023-507325-42-00 5 countries 2024 n=282
    Ended
  • Intra-Cellular Therapies Inc. Commercial
    ITI-1284
    2024-513035-25-00 8 countries 2025 n=216
    Recruiting
  • Intra-Cellular Therapies Inc. Commercial
    ITI-1284
    2024-514680-26-00 6 countries 2025 n=137
    Ended
  • Immungenetics AG Academic
    FLORBETABEN (18F)
    2022-501137-23-00 1 country n=228
    Ended
  • Region Skane Academic
    2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
    2024-511842-38-00 1 country 2017 n=2,450
    Recruiting

Phase I (Other)

1 trial
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-514634-20-00 3 countries 2025 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol-Myers Squibb Services Unlimited Company Commercial 6 Phase III 5
Acadia Pharmaceuticals Inc. Commercial 2 Phase II, Phase III 1
Intra-Cellular Therapies Inc. Commercial 2 Phase II 1
Karuna Therapeutics Inc. Commercial 2 Phase III 1
Otsuka Pharmaceutical Development & Commercialization Inc. Commercial 2 Phase III 0
Institut National De La Sante Et De La Recherche Medicale Academic 2 Phase II/III 0
Janssen - Cilag International Commercial 1 Phase I (Other) 0
Suven Life Sciences Limited Commercial 1 Phase III 1
Immungenetics AG Academic 1 Phase II 0
Region Skane Academic 1 Phase II 1
New trials by year
2021
2
2022
1
2024
4
2025
8
← All indication landscapes